| Manufacturer ▼ | Drug Name | Indication | Stage | Status | Route of Administration | Drug Class |
|---|---|---|---|---|---|---|
| Notable Labs Ltd. | VB-201 | COVID-19 | Phase 2 | Oral | COVID-19 | |
| Notable Labs Ltd. | VB-111 and OPDIVO (nivolumab) | Colorectal Cancer | Phase 2 | Intravenous | Oncology | |
| Notable Labs Ltd. | Ofra-vec (VB-111) | Recurrent glioblastoma multiforme (rGBM) | Phase 2 | Intravenous | Oncology | |
| Notable Labs Ltd. | VB-201 | Psoriasis | Phase 2 | Oral | Immunology | |
| Notable Labs Ltd. | VB-201 | Ulcerative colitis | Phase 2 | Oral | Gastroenterology | |
| Notable Labs Ltd. | Volasertib | Relapsed/refractory acute myeloid leukemia | Phase 2 | IND Clearance | Intravenous | Oncology |
| Notable Labs Ltd. | Fosciclopirox | Relapsed/refractory acute myeloid leukemia, R/R AML | Phase 2a | Data Released | Oral | Oncology |
| NovaBridge Biosciences | Felzartamab (TJ202/MOR202) | Third-line multiple myeloma | BLA Filing | Trial Planned | Intravenous | Oncology |